6 investors discuss why AI is more than just a buzzword in biotech
TechCrunch
DECEMBER 15, 2022
“Most of the companies we have seen have an AI component to support the discovery or development processes,” Francisco Dopazo, a general partner at Humboldt Fund told TechCrunch recently. Results, whether in the form of novel therapeutic programs, diagnostic capabilities or other clinically meaningful outcomes, are necessary.
Let's personalize your content